Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop

The Process Of Discovering And Developing A New Drug Or Therapy Is Extremely Costly And Time Consuming, And Recently, It Has Been Estimated That The Creation Of A New Medicine Costs On Average More Than Siobhan Addie, Amanda Wagner Gee, Steve Olson, And Sarah H. Beachy, Rapporteurs, Roundtable On Genomics And Precision Health, Forum On Drug Discovery, Development, And Translation, Board On Health Sciences Policy, Health And Medicine Division, National Academies Of Sciences, Engineering, And Medicine. Includes Bibliographical References (pages 59-63). This Project Was Supported By Contracts Between The National Academy Of Sciences And 23andme (unnumbered Contract); Abbvie Inc. (unnumbered Contract); American Academy Of Nursing (unnumbered Contract); American College Of Medical Genetics And Genomics (unnumbered Contract); American Diabetes Association (unnumbered Contract); American Heart Association (unnumbered Contract); American Medical Association (unnumbered Contract); American Society Of Human Genetics (unnumbered Contract); American Society Of Microbiology (unnumbered Contract); Amgen Inc. (contract No. Ghccops-csarf-85167); Association For Molecular Pathology (unnumbered Contract); Association Of American Medical Colleges (unnumbered Contract); Astrazeneca (unnumbered Contract); Baxter Bioscience (unnumbered Contract); Biogen (unnumbered Contract); Blue Cross And Blue Shield Association (unnumbered Contract); Burroughs Wellcome Fund (contract No. 1016598); Centers For Disease Control And Prevention (contract No. 200-2011-38807, Order No. 0039); College Of American Pathologists (unnumbered Contract); Critical Path Institute (unnumbered Contract); Department Of Veterans Affairs (contract No. Va240-14-c-0037); Doris Duke Charitable Foundation (contract No. 2015103); Eli Lilly And Company (unnumbered Contract); Fastercures (unnumbered Contract); Friends Of Cancer Research (unnumbered Contract); Genedx (unnumbered Contract); Glaxosmithkline (contract No. 016084); Health Resources And Services Administration (contract No. Hhsh250200976014i, Order No. Hhsh25034017t And Hhsh250201500001i, Order No. Hhsh25034003t); International Society For Cardiovascular Translational Research (unnumbered Contract); Janssen Research & Development, Llc (unnumbered Contract); Johnson & Johnson (unnumbered Contract); Kaiser Permanente Program Offices Community Benefit Ii At The East Bay Community Foundation (unnumbered Contract); Merck & Co., Inc. (contract No. Cmo-140505-000393, Contract No. Cmo-150107-000659, And Contract No. Cmo-160208-001245); National Institutes Of Health (contract No. Hhsn263201200074i; Task Order Nos. Hhsn26300005/0002, Hhsn26300066, And Hhsn26300093: National Cancer Institute; National Center For Advancing Translational Sciences; National Human Genome Research Institute; National Institute Of Allergy And Infectious Diseases; National Institute On Aging; National Institute Of Mental Health; National Institute Of Neurological Disorders And Stroke; And National Institute Of Nursing Research); National Society Of Genetic Counselors (unnumbered Contract); New England Journal Of Medicine (unnumbered Contract); Northrop Grumman Health It (unnumbered Contract); Pfizer Inc. (unnumbered Contract); Phrma (unnumbered Contract); Sanofi (unnumbered Contract); And Takeda Pharmaceuticals (contract No. 53108); And U.s. Food And Drug Administration (contract No. 1r13fd005496-01). Any Opinions, Findings, Conclusions, Or Recommendations Expressed In This Publication Do Not Necessarily Reflect The Views Of Any Organization Or Agency That Provided Support For The Project.